Syncom Formulations (India) vs Peers
- Market cap
- ₹2,183 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹16.72 – ₹31.35
Syncom Formulations (India) ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Syncom Formulations (India). Its P/E of 22.5 compares with a peer median of 22.5.
Syncom Formulations (India) vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Syncom Formulations (India) | 23.22 | -1.48% | 2,183 | 22.5 | 2.85 | 14.5% | +18.5% |
| Syncom Formulations (India) | 23.22 | -1.48% | 2,183 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Syncom Formulations (India) peer comparison — frequently asked questions
Who are Syncom Formulations (India)'s competitors?
Syncom Formulations (India)'s listed peers in Drug Manufacturers - Specialty & Generic include Syncom Formulations (India), ranked here by market capitalisation.
How does Syncom Formulations (India)'s P/E compare with its peers?
Syncom Formulations (India) trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Syncom Formulations (India)'s peers?
By market capitalisation, the largest company in the group is Syncom Formulations (India) at ₹2,183 crore, against ₹2,183 crore for Syncom Formulations (India).
Same Data For Peers
Trade Syncom Formulations (India) With ATS
Track SYNCOMF live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.